1-800-887-8100
COPAXONE® (glatiramer acetate injection) 40 mg/mL Logo
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
MENU
Shared Solutions®
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
Copaxone® is the #1 prescribed brand for relapsing MS in the US 1*

Teva’s Shared Solutions® is committed to help you and your staff

Teva’s Shared Solutions® can take care of many important behind-the-scenes details so you can focus on treating your patients

Office in-service visits

Teva’s Shared Solutions® understands how important patient care and education are to your office, and we want to do everything we can to help you and your staff learn about the full breadth of services available to your patients. This is why Teva-trained nurses provide education and training on Shared Solutions® and COPAXONE® therapy at any time the training is needed.

CNE support for healthcare professionals

Teva’s Shared Solutions® cares about providing in-person support and communications you need to help manage your patients on COPAXONE®. Our Clinical Nurse Educators (CNEs) can help provide regular updates on injection training and nursing support that we've provided for your patients.

View the full range of CNE services

Healthcare professional line at Shared Solutions®

Teva’s Shared Solutions® cares about providing support to busy healthcare professionals — because your time is valuable, there is a dedicated phone line for you and your staff. This means that when you call Shared Solutions®, you can get the information you need quickly.

Explore milestones in the development of COPAXONE® as an enduring option in relapsing MS care.
VIEW OUR TIMELINE
In-home initial injection trainings help support patients' injection experience
Learn more
Teva’s Clinical Nurse Educators (CNEs) offer personalized services and support for you, your patients, and the RMS community
View CNE services

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

IMPORTANT SAFETY INFORMATION

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of

You are now leaving this website

The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.

While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.

Continue to site
×